Johnson & Johnson’s investigational COVID-19 vaccine entered Phase 3 clinical trials this week, making it the fourth vaccine candidate in the U.S. to do so and providing additional details that can help investors differentiate the pool of late-stage coronavirus vaccines. Shares of J&J JNJ, +0.68% were up 0.3% in trading …
Read More »There are four coronavirus vaccines in late-stage studies — here’s how they differ
